Systematic (IUPAC) name | |
---|---|
1-N-(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-3-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide | |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Pregnancy cat. | B(US) |
Legal status | ℞-only (US) |
Routes | intravenously |
Pharmacokinetic data | |
Bioavailability | N/A |
Protein binding | negligible |
Half-life | 2 hours |
Excretion | Mostly renal |
Identifiers | |
CAS number | 107793-72-6 |
ATC code | V08AB12 |
PubChem | CID 3743 |
ChemSpider | 3612 |
UNII | A4YJ7J11TG |
KEGG | D02161 |
ChEMBL | CHEMBL1201075 |
Chemical data | |
Formula | C18H24I3N3O8 |
Mol. mass | 791.112 |
SMILES | eMolecules & PubChem |
|
|
(verify) |
(what is this?)
Ioxilan is a diagnostic contrast agent. It is injected intravenously before taking X-ray images to increase arterial contrast in the final image. It is marketed under the trade name Oxilan by Guerbet, L.L.C.
|